Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 14/20 | 0.35 |
| ▸ | F7 | P08709 | 14/20 | 0.35 |
| ▸ | F10 | P00742 | 13/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | LIG1 | P18858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137124 | 0.89 | F11 (0.35) | MEN1ALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL16239630 | 0.85 | — | — | |
| SCHEMBL2133131 | 0.82 | KDM4E (0.38) | MEN1ALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL2134792 | 0.82 | NPC1 (0.31) | ALDH1A1KDM4E | |
| SCHEMBL2134564 | 0.79 | GRIN2B (0.36) | ALDH1A1F11F7F10 | |
| SCHEMBL2136073 | 0.79 | PRKAG1 (0.37) | MAPTF11F7F10 | |
| SCHEMBL2133024 | 0.79 | GRIN2B (0.35) | ALDH1A1F11F7F10 | |
| SCHEMBL16239484 | 0.79 | — | — | |
| SCHEMBL2135981 | 0.77 | F10 (0.43) | MEN1ALDH1A1KMT2AMAPTF11 | |
| SCHEMBL2138497 | 0.77 | HSPA9 (0.39) | ALDH1A1KDM4EF11F7F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | claimed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | claimed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | claimed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | claimed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | claimed |
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | PRKAG1, PRKAB1, PRKAG2 | MEN1 2624/4885ALDH1A1 624/4885KMT2A 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.